GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » YoY EPS Growth

PCI Biotech Holding ASA (FRA:4QG) YoY EPS Growth : 0.00% (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. PCI Biotech Holding ASA's YoY EPS Growth for the quarter that ended in Dec. 2024 was 0.00%.

PCI Biotech Holding ASA's Earnings per Share (Diluted) for the six months ended in Dec. 2024 was €-0.02.


PCI Biotech Holding ASA YoY EPS Growth Historical Data

The historical data trend for PCI Biotech Holding ASA's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA YoY EPS Growth Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.78 -27.87 39.74 66.67 21.28

PCI Biotech Holding ASA Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.41 72.45 55.56 37.04 -

PCI Biotech Holding ASA YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

PCI Biotech Holding ASA's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(-0.037--0.047)/ | -0.047 |
=21.28 %

PCI Biotech Holding ASA's YoY EPS Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EPS Growth (Q: Dec. 2024 )
=(Earnings per Share (Diluted) (Q: Dec. 2024 )-Earnings per Share (Diluted) (Q: Dec. 2023 )) / | Earnings per Share (Diluted) (Q: Dec. 2023 )) |
=(-0.02--0.02)/ | -0.02 |
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines